Announcements Trials
Browse Landscape

Phase

Phase 2 59Phase 3 29Phase 1 17Phase 1/2 15Phase 2/3 5Phase 4 2Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Myasthenia Gravis 1Metastatic Castration-resistant Prostate Cancer 1Adrenal Insufficiency 1

Interventions

Letrozole 5Tamoxifen 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Injections 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3trametinib 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Specimen Handling 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Oxaliplatin 2Medroxyprogesterone Acetate 2Leucovorin 2Lenalidomide 2Ipilimumab 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Prednisone × 90 days × Clear all
NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

AstraZeneca

Phase 4 Active not recruiting
43 enrolled 16 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡